menu
    • menu

    Company profile for NeuClone

    NEW Drugs in Dev: 1
    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    Contact Supplier

    LEBSA- Your strategic API source for niche molecules.

    Virtual Booth

    Contact Supplier

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    NeuClone is a clinical-stage biopharmaceutical company, with an exclusive focus on the development and commercialisation of high quality biosimilar products. Our vision is increasing affordability and patient access to life saving and life extending therapies. Led by a team of industry veterans, we are focused on creating a deep pipeline of high quality biosimilars at a scale and price that meets demands of global markets. We ...
    NeuClone is a clinical-stage biopharmaceutical company, with an exclusive focus on the development and commercialisation of high quality biosimilar products. Our vision is increasing affordability and patient access to life saving and life extending therapies. Led by a team of industry veterans, we are focused on creating a deep pipeline of high quality biosimilars at a scale and price that meets demands of global markets. We value affordable access to healthcare, the quality and integrity of our science, and a strong patient focus.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    NeuCloneAustralia Flag
    Country
    Country
    Australia
    Address
    Address
    Australian Technology Park, National Innovation Centre 4 Cornwallis Street, E...
    Telephone
    Telephone
    +612 9209 4020
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://neuclone.com/
    Linkedin
    Linkedin
    https://in.linkedin.com/company/neuclone-pty-ltd
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    NeuClone Announces Positive Results from Phase I Study of Stelara® (ustekinumab)
    NeuClone Announces Positive Results from Phase I Study of Stelara® (ustekinumab)

    20 Oct 2020

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20201020005445/en

    BUSINESSWIRE
    20 Oct 2020
    Share Share
    NeuClone Discloses Two Biosimilars Referencing Opdivo® and Keytruda®
    NeuClone Discloses Two Biosimilars Referencing Opdivo® and Keytruda®

    01 Sep 2020

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20200901005308/en/NeuClone-Discloses-Biosimilars-Referencing-Opdivo%C2%AE-Keytruda%C2%AE#:~:text=NeuClone%20Discloses%20Two%20Biosimilars%20Referencing%20Opdivo%C2%AE%20and%20Keytruda,-%C2%AE&text=These%20biosimilars%20reference%20two%20antibody,patients%20across%20multiple%20oncology%20settings.

    BUSINESSWIRE
    01 Sep 2020
    Share Share
    NeuClone Announces Completion of Subject Visits in Stelara® (ustekinumab
    NeuClone Announces Completion of Subject Visits in Stelara® (ustekinumab

    08 Apr 2020

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20200408005128/en

    BUSINESSWIRE
    08 Apr 2020
    Share Share
    NeuClone Announces Completion of Subject Visits in Stelara® (ustekinumab)
    NeuClone Announces Completion of Subject Visits in Stelara® (ustekinumab)

    08 Apr 2020

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20200408005128/en/NeuClone-Announces-Completion-Subject-Visits-Stelara%C2%AE-ustekinumab/?feedref=JjAwJuNHiystnCoBq_hl-QyNsUQ29c24MKpwrFSKUOTZQK86VRF04E6aMvZHPoaH7fxFuNFTHSunhvli30RlBNXya2izy9YOgHlBiZQk2LP6oD-t3eB0qV-nJQ-WeFyCEq7XOd8em_Uy42DWNTo2Mw==

    BUSINESSWIRE
    08 Apr 2020
    Share Share
    ​NeuClone Completes Dosing in Phase I Clinical Trial of Stelara
    ​NeuClone Completes Dosing in Phase I Clinical Trial of Stelara

    18 Dec 2019

    // BUSINESS WIRE

    https://www.businesswire.com/news/home/20191218005072/en/%E2%80%8BNeuClone-Completes-Dosing-Phase-Clinical-Trial-Stelara%C2%AE

    BUSINESS WIRE
    18 Dec 2019
    Share Share
    NeuClone Announces Positive Results from Phase I Study of Herceptin
    NeuClone Announces Positive Results from Phase I Study of Herceptin

    05 Dec 2019

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20191205005324/en

    BUSINESSWIRE
    05 Dec 2019
    Share Share

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search